Zai Lab (NASDAQ:ZLAB) Insider Sells $202,064.90 in Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) insider Rafael Amado sold 9,910 shares of the stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $20.39, for a total value of $202,064.90. Following the transaction, the insider directly owned 59,761 shares in the company, valued at approximately $1,218,526.79. This represents a 14.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Rafael Amado also recently made the following trade(s):

• On Friday, March 13th, Rafael Amado sold 2,957 shares of Zai Lab stock. The stock was sold at an average price of $18.63, for a total value of $55,088.91.

Zai Lab Price Performance

Shares of Zai Lab stock opened at $20.41 on Monday. Zai Lab Limited Unsponsored ADR has a 12-month low of $15.96 and a 12-month high of $44.34. The stock has a 50 day moving average price of $18.67 and a two-hundred day moving average price of $21.68. The stock has a market capitalization of $2.30 billion, a P/E ratio of -12.68 and a beta of 0.86.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings results on Saturday, February 14th. The company reported ($0.50) EPS for the quarter. The firm had revenue of $127.60 million during the quarter. Zai Lab had a negative net margin of 38.15% and a negative return on equity of 22.81%. Sell-side analysts anticipate that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Zai Lab stock. SG Americas Securities LLC acquired a new stake in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 9,754 shares of the company’s stock, valued at approximately $331,000. Institutional investors and hedge funds own 41.65% of the company’s stock.

Wall Street Analyst Weigh In

ZLAB has been the subject of a number of research analyst reports. Cantor Fitzgerald cut their target price on shares of Zai Lab from $55.00 to $37.00 and set an “overweight” rating for the company in a research report on Friday, February 27th. UBS Group assumed coverage on Zai Lab in a research note on Wednesday, January 7th. They issued a “buy” rating and a $35.00 price objective on the stock. Zacks Research cut Zai Lab from a “hold” rating to a “strong sell” rating in a research report on Friday, January 23rd. Jefferies Financial Group upgraded Zai Lab to a “strong-buy” rating in a research note on Monday, January 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zai Lab in a report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.